Telix Resubmits NDA for TLX101-Px Brain Cancer Imaging Agent
MELBOURNE, Australia and INDIANAPOLIS, United States, March 16, 2026 Telix Pharmaceuticals has announced the resubmission of a New Drug...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MELBOURNE, Australia and INDIANAPOLIS, United States, March 16, 2026 Telix Pharmaceuticals has announced the resubmission of a New Drug...
Melbourne, Australia & Indianapolis, United States – March 10, 2026 Telix Pharmaceuticals has announced that Part 1 of the...
